Skip to content

Neuropace, Inc. NPCE Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Medtronic logo
MedtronicMDT
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
ITG
Integer HoldingsITGR

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s remainder of fiscal year 2024?
Neuropace, Inc. (NPCE) reported remainder of fiscal year 2024 of $2.27M in Q1 2026.
How has Neuropace, Inc.'s remainder of fiscal year 2024 changed year-over-year?
Neuropace, Inc.'s remainder of fiscal year 2024 increased by 3.0% year-over-year, from $2.21M to $2.27M.